- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: anifrolumab-fnia | MDX-1333 | MEDI-546 | Saphnelo®
anifrolumab is an approved drug (FDA (2021), EMA (2022))
Compound class: Antibody
Comment: Anifrolumab is a monoclonal antibody targeting IFNAR1 (the receptor for α, β and ω interferons), that was developed by the MedImmune subsidiary of AstraZeneca as a treatment for systemic lupus erythematosus (SLE).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. . Sequence BLAST using the heavy and light chain variable regions of anifrolumab provides 100% matches to sequences that are claimed in patent US7662381 . The sequence matches identify anifrolumab as clone 11E2 in the patent.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Anifrolumab acts to block IFNα binding to its cognate receptor, thereby preventing IFNAR1 activation.
|Systemic lupus erythematosus
|Approved therapy for SLE.
|Clinical candidate for scleroderma.